

# Current trends in vestibular schwannoma management at a referral center in Indonesia: A cross-sectional study with retrospective data collection

Renindra Ananda Aman<sup>1</sup>, Nadya Zaragita<sup>1</sup>, Fitrie Desbassarie<sup>1</sup>, Bima Andyan Wicaksana<sup>1</sup>, Nicholas Calvin<sup>2</sup>

<sup>1</sup>Department of Neurosurgery, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

<sup>2</sup>Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

## ABSTRACT

**Background.** Vestibular schwannoma (VS) is the most common benign brain tumor of the cerebellopontine angle. Due to its location, this pathology can create both focal and general deficits. The registry system for VS in Indonesia is developing, including in the author's institution, which eventually shows a changing trend in managing VS.

**Methods.** We retrospectively collected data from all patients diagnosed with vestibular schwannoma, based on histological or radiological results. Treatments included craniotomy and/or Gamma Knife Radiosurgery (GKRS) from 2018 to 2023.

**Results.** Data from 88 patients were analyzed. The number of treated patients has increased annually. VS predominantly affects females (64%). The proportion between GKRS and craniotomy procedures also shifted throughout the year. Common symptoms included hearing loss (63.6%), disequilibrium (50%), and headaches (39.7%). The most common tumor size was medium (15-30 mm; n=37; 42%). Tumors that fell into the intrameatal and small (<15 mm) categories were all treated with GKRS, whereas the other groups were divided into GKRS and craniotomy. GKRS demonstrated high efficacy in tumor control and favorable hearing and facial nerve preservation, whereas craniotomy remained crucial for larger tumors.

**Conclusion.** The number of VS diagnosed each year has increased in our center, accompanied by a noticeable shift in preference from GKRS to craniotomy, which is influenced by the integration of intraoperative monitoring. Treatment preference was further determined based on the clinical profile and tumor size. In the future, there is a need to develop a national registry to better reflect the true incidence of VS within the Indonesian population.

**Keywords:** vestibular schwannoma, gamma knife radiosurgery, craniotomy, intraoperative monitoring, national registry

## Abbreviations (in alphabetical order):

COVID-19 – coronavirus disease 2019  
CPA – cerebellopontine angle  
CSF – cerebrospinal fluid  
GKRS – gamma knife radiosurgery  
ICP – intracranial pressure  
IOM – intraoperative monitoring  
MRI – magnetic resonance imaging

NF2 – neurofibromatosis type 2  
RSCM – Dr. Cipto Mangunkusumo National General Hospital  
SRS – stereotactic radiosurgery  
VP – ventriculoperitoneal  
VS – vestibular schwannoma

Corresponding author:  
Renindra Ananda Aman  
E-mail: reninananda.aman@ui.ac.id

Article History:  
Received: 20 March 2024  
Accepted: 28 June 2024

## BACKGROUND

Vestibular schwannoma (VS) is the most common benign tumor of the cerebellopontine angle (CPA). This pathology makes up 6-8% of all primary brain tumors. Despite its benign nature, the location, the relationship to adjacent structures, and the compression effect of the tumor may cause morbidity and mortality [1]. VS is often marked by hearing loss and disequilibrium, and is often associated with other cranial nerve deficits. Tumor size and direction of tumor growth also affect the progression of symptoms. More recently, VS cases are diagnosed when sizes are relatively small, likely due to better access to healthcare facilities [2].

Globally, incidence rates of VS vary in different geographical locations [2]. However, epidemiological studies of VS in Indonesia are still limited. The national registry system is still under development, and the data from individual centers are not yet unified. Therefore, the current management of VS in different areas of the country may not be the same. In rural areas, when cases of hydrocephalus appear, a cerebrospinal fluid (CSF) diversion procedure is performed; however, the definitive management of the tumor itself is performed after being referred to a higher-level center.

VS management varies, and choices are made according to the severity of the disease, tumor size, and extent of tumor growth. Within the last few decades, less invasive modalities such as external beam radiotherapy and Gamma Knife radiosurgery (GKRS) have been widely used, especially for smaller tumors (diameter <3 cm) [3]. Larger tumors require surgical intervention, and the emerging, widely used now, intraoperative monitoring (IOM) has become increasingly prevalent. This technology aids neurosurgeons in preserving functional integrity during surgery.

### Comparison to global trends and unique challenges in Indonesia

Compared to global trends, the prevalence and management of VS in Indonesia face unique challenges. In developed countries, the incidence of VS has been increasing, partly due to improved diagnostic capabilities. In Indonesia, however, the absence of a unified registry and the disparity in healthcare access between urban and rural areas contribute to inconsistent data – where the number of VS diagnoses is concentrated in urban areas. Furthermore, advanced treatment modalities like GKRS and IOM are predominantly available in major cities, making them less accessible in rural regions. In these rural areas, CSF diversion is more commonly performed to manage hydrocephalus, one of the possible complications of VS.

Unique factors influencing VS management in Indonesia include the geographic distribution of healthcare facilities, economic constraints, and the varying levels of medical expertise across the country. Additionally, cultural beliefs, education, and awareness levels about tumors can impact patients' willingness to seek early medical intervention.

### Impact on clinical practice and policy

The findings of this study could significantly impact clinical practice and policy in Indonesia. By highlighting the current trends and challenges in VS management, this research can inform healthcare providers and policymakers about the areas needing improvement. The establishment of a comprehensive national registry could standardize data collection and improve epidemiological understanding. Increasing access to accurate and advanced diagnostic and treatment facilities, as well as providing expert healthcare professionals in rural areas could bridge the gap in healthcare delivery.

Moreover, this study represents a crucial first step towards establishing a comprehensive national registry for VS in Indonesia. By initially providing detailed data from a national referral center, the authors aim to pave the way for future contributions from other centers, encompassing both urban and rural areas. This study presents a cross-sectional analysis with retrospective data collection of VS cases treated at Dr. Cipto Mangunkusumo National General Hospital (Rumah Sakit Cipto Mangunkusumo/RSCM) in Jakarta, from 2018 to 2023. As a national referral hospital, it plays a pivotal role in admitting VS cases from district hospitals in various parts of the country. The findings of this study provide valuable insight into the current landscape of VS management in Indonesia, highlighting unique challenges. These insights are invaluable for informing improvements in clinical practice and shaping future healthcare policies.

## METHODS

### Study design and data extraction

A cross-sectional analysis with retrospective data collection was conducted from 2018 to 2023 at RSCM in Jakarta, Indonesia. The data of patients diagnosed with VS were systematically collected. The diagnosis of VS was established through either histopathological examination or radiological assessment, primarily based on gadolinium-enhanced magnetic resonance imaging (MRI). All data were meticulously extracted from the hospital medical records. Specifically, information was retrieved from presentation and discussion materials during pre-operative and post-operative meetings held at the neurosurgery de-

partment of RSCM. These routine meetings document comprehensive data relevant to VS diagnosis, treatment, and outcomes, providing a comprehensive source for this research preparation. The collected data were analyzed and methodically presented through structured tables and charts.

### Study population and eligibility criteria

This study includes all individuals who were diagnosed with VS based on histopathological or brain MRI findings during 2018 to 2023 in RSCM hospital. This study also encompasses all therapeutic interventions chosen, including GKRS, craniotomy, and CSF diversion procedures. Patients under 18 years of age were excluded from the analysis.

### Evaluation and report of variables

This study also systematically evaluated various variables to explore the management of VS in RSCM comprehensively. The evaluated key variables included sex, age group, size, and lateralization of tumors, offering insights into the demographic and anatomical dimensions of VS. This study also meticulously dissected other variables explored, including clinical presentations and symptomatology, types of referring physicians, surgical decisions regarding GKRS and craniotomy, clinical course of the disease, and postoperative outcomes. These variables were chosen to provide a comprehensive perspective of VS in a national referral center in Indonesia, which encompasses demographic, anatomical, clinical, and procedural dimensions of VS management.

### Statistical methods

This study presents data using descriptive statistics, including counts and percentages for categorical variables, and mean or median for numerical variables. The choice between mean and median was determined based on the normality test of the data using the Kolmogorov-Smirnov method. If the data followed a normal distribution, the mean and standard deviation were calculated and reported; otherwise, non-normally distributed data were summarized using the median and range. All statistical analyses were conducted using IBM SPSS Statistics version 25 software.

## RESULTS

From 2018 to 2023, 88 patients in RSCM were diagnosed with vestibular schwannoma on the basis of histopathological or brain MRI findings. All patients were included in this study, as they fulfilled the inclusion criteria. The number of treated cases increased throughout the year, and the proportion between GKRS and craniotomy also shifted (Table 1).

**TABLE 1.** Distribution of treated vestibular schwannoma cases based on craniotomy and GKRS procedures

Year	Craniotomy (n)	GKRS (n)	Treated cases (n)
2018	1	7	8
2019	1	14	15
2020	2	13	15
2021	4	16	20
2022	5	6	11
2023	12	8	20

**TABLE 2.** Demographic characteristics of vestibular schwannoma patients in RSCM

Demographics	Number (n=88)	Percentage (%)
<b>Sex</b>		
Female	56	64
Male	32	36
<b>Age (median)</b>		
<40 years	29	33
40-49 years	18	21
50-59 years	28	32
60-69 years	11	12,5
>69 years	2	2,3
<b>By size</b>		
Intrameatal	7	8
Small	1	1.1
Medium	37	42
Large	19	21.5
Giant	24	27.2
<b>Koos grading</b>		
I	11	12.5
II	5	5.7
III	10	11.4
IV	62	70.5
<b>Median volume (cm<sup>3</sup>)</b>	11.3 (0.027– 165)	
<b>Lateralization</b>		
Right	37	42
Left	47	53.4
Bilateral	4	4.5
<b>Types of referring physicians</b>		
Neurosurgeons in RSCM	25	28.4
Neurosurgeons outside RSCM	31	35.2
Other specialities in RSCM	16	18.2
Other specialities outside RSCM	17	19.3
General physicians	0	0

According to the results in Table 2, there were 56 (64%) female and 32 (36%) male patients with a median age 48.5 for all cases. The median age was 43 years, with cases more often found in the <40 years age group (n=29; 33%). Based on tumor size, the authors classified them into four groups: intrameatal,

small (diameter <15 mm), medium (diameter 15-30 mm), large (diameter 30-40 mm), and giant (>40 mm). According to the Koos grading scale, the majority of the tumors were classified as Grade IV, comprising 70.5% of the cases. Koos Grade I held a 12.5% share and Grade III represented 11.4% of the cases, while Koos Grade II has the smallest percentage of 5.7%. The median volume of all vestibular schwannoma (VS) patients treated at RSCM from 2018 to 2023 is 11.3 cm<sup>3</sup>, ranging from 0.027 cm<sup>3</sup> to 165 cm<sup>3</sup>.

In the analysis of tumor lateralization, tumor distribution showed a slight left-sided predominance (53.4%) compared to the right (42%). Bilateral occurrences were observed in 4.5% of the cases. These findings underscore the lateralization tendency in VS, highlighting the relevance of considering the tumor side in diagnostics and treatment, particularly for bilateral VS, which requires further evaluation for other plausible conditions.

Table 2 also provides a breakdown of the types of physicians involved in referring patients with VS to the neuro-oncology division within the Department of Neurosurgery at RSCM, where both the GKRS and surgical approaches are performed. Notably, neurosurgeons play a central role in the referral system, both within the RSCM (28.4%) and external to the RSCM (35.2%), indicating reliance on neurosurgical expertise in the referral system. Other specialties, both internal and external to RSCM, play a comparatively smaller role. Moreover, there is an absence of direct referrals from general physicians to the neuro-oncology division of the neurosurgery department in RSCM.

In terms of symptomatology (Table 3), the majori-

**TABLE 3.** Signs and symptoms of vestibular schwannoma

Symptoms	Number (n=88)	Percentage (%)
Hearing loss	63	71.5
Tinnitus	22	25
Disequilibrium	44	50
Facial nerve palsy	22	25
Trigeminal nerve deficits	18	20.4
Dysarthria	10	11.3
Dysphagia	10	11.3
Headache	33	39.7
Visual impairments	11	12.5
Cerebellar signs	4	4.5
Hemiparesis	3	3.4
Hemihypesthesia	1	1.1

ty of patients who visited our center presented with symptoms of hearing loss (71.5%). This underscores the significant auditory impact of tumors. Tinnitus affected 25% of patients, while disequilibrium was notable in 50% of the cases. Facial nerve palsy and trigeminal deficits were observed in 25% and 20.4%

**TABLE 4.** Intervention-related variables of vestibular schwannoma patients in RSCM

Variables	Number (n=88)	Percentage (%)
<b>Types of intervention</b>		
GKRS	60	68.2
Craniotomy	28	31.8
<b>Mean duration from initial symptoms to intervention</b>	25 months (1-161)	
<b>GKRS (n=60)</b>		
Median volume	8 cm <sup>3</sup> (0.027-40.9)	
Median maximum diameter	2.6 cm (0.2-6.2)	
Median dose	15.20 Gy (8-52)	
Median isodose line	50 ± 2.6%	
<b>Indications for GKRS</b>		
<i>Maximum tumors diameter &lt;3 cm</i>	46	76.7
<i>Hearing and facial nerve preservation</i>	9	15
<i>Surgeons' preference</i>	5	8.3
<b>Craniotomy (n=28)</b>		
<b>Indications for surgery</b>		
<i>Large and giant tumors (&gt;3cm)</i>	27	96.4
<i>Severe neurological deficit</i>	1	3.6
<b>Extent of surgical resection</b>		
<i>Gross total resection</i>	8	28.6
<i>Near total resection</i>	11	39.3
<i>Subtotal resection</i>	9	32.1

of the patients, respectively. Dysarthria and dysphagia were present in approximately 11% of cases. In addition to the primary symptoms, 39.7% reported headaches and 12.5% experienced visual impairments. Less frequently, cerebellar signs, hemiparesis, and hemihypesthesia were observed. This reveals the diverse manifestations associated with vestibular schwannomas, which can give rise to auditory, neurological, and other secondary symptoms.

Based on the results in table 4, sixty patients underwent GKRS, and 28 underwent craniotomy. One patient underwent two re-craniotomy procedures and one patient underwent two GKRS procedures. The mean duration from initial symptoms to interventions was reported to be 25 months, with a wide range of 1 to 161 months.

Various parameters are highlighted for the GKRS cases. The median volume of tumors treated is 8 cm<sup>3</sup> (0.027- 40.9). The median maximum diameter is 2.6 cm (0.2-6.2). The radiation dose administered shows a median of 15.20 Gy (8-52). The median isodose line was 50 ± 2.6%. Most patients who underwent GKRS were in the intracanalicular, small, and medium tu-

mor groups, which contributed to 76.7% of the patients who underwent GKRS.

Ten patients (16.7%) with large tumors and four patients (6.7%) with giant tumors underwent GKRS procedures. These interventions were chosen for reasons other than tumor size, including preservation of hearing and facial nerves (15%) and based on surgeons' preference (8.3%).

In contrast, patients who underwent craniotomy had medium (1, 3.6%), large (9, 32.1%), and giant (16, 57.1%) tumors. Medium-sized tumors were considered for craniotomy due to the severe neurological deficits experienced by the patient. IOM was used in most craniotomy procedures and all procedures were performed using the retrosigmoid approach. Further analysis of craniotomy cases revealed the extent of surgical resection. Gross total resection was achieved in 28.6% of the cases, near-total resection in 39.3%, and subtotal resection in 32.1%.

The most prevalent immediate symptom after the intervention was hearing loss, reported by 65 individuals, which decreased to 42 after a year (Table 5). Tinnitus, disequilibrium, and facial nerve palsy were also common initially but exhibited a decline over the follow-up period. Notably, dizziness and trigeminal deficits were reported in a small proportion of individuals and remained relatively stable. Other symptoms, such as dysarthria, dysphagia, headache, visual impairments, cerebellar signs, hemiparesis, hemihypesthesia, ptosis, and death, demonstrated varying degrees of occurrence and persistence across different time points. These data indicate the dynamic nature of post-event symptoms, with some resolution, while others persist or emerge during the fol-

**TABLE 5.** Symptoms during follow-up in vestibular schwannoma patients in RSCM

Symptoms (n=88)	Immediate	3 months	6 months	12 months
Hearing loss	65	61	52	42
Tinnitus	21	21	18	12
Disequilibrium	39	31	30	26
Dizziness	8	3	2	2
Facial nerve palsy	30	23	20	15
Trigeminal deficits	20	16	14	12
Dysarthria	12	6	4	3
Dysphagia	12	6	4	3
Headache	17	15	11	9
Visual impairments	11	10	8	6
Cerebellar signs	13	6	5	3
Hemiparesis	4	2	2	1
Hemihypesthesia	1	1	1	1
Ptosis	1	1	1	1
Death	-	2	-	-
Loss to follow up	-	4	-	1

low-up period. Failure to follow-up occurred in a small number of cases (n=5, 5%), introducing a potential source of bias in the reported outcomes.

According to the results in Table 6, hearing preservation emerged as a notable achievement in this study, with 92% of the patients experiencing successful preservation of hearing. Similarly, facial nerve preservation was achieved in 67.2% of cases, demonstrating a considerable success rate in maintaining facial nerve function.

**TABLE 6.** Post-operative outcomes of vestibular schwannoma patients in RSCM

Variables	Number	Percentage (%)
Hearing preservation	23	92
Facial nerve preservation	39	67.2
Median length of hospital stay	5 (2-17) days	31.8
<b>GKRS</b>		
Mean follow-up duration	11.3 ± 2.3 months	
Mean length of hospital stay	4.9 ± 2.1 days	
Tumor control	57	95.5
Mean relative volume reduction	34 ± 6.7 %	
<b>Hearing preservation</b>		
Hearing preservation	18/20	90
No hearing preservation	2/20	10
Hearing improvement	17/28	60.7
No hearing improvement	11/28	39.3
<b>Facial nerve preservation</b>		
Facial nerve preservation	36/38	94.7
No facial nerve preservation	2/38	5.3
Facial nerve improvement	4/8	50
No facial nerve improvement	4/8	50
Mortality	0	0
<b>Craniotomy</b>		
Mean follow-up duration	11.5 ± 1.6 months	
Mean length of hospital stay	6.3 ± 3.6 days	
<b>Hearing preservation</b>		
Hearing preservation	3/5	60
No hearing preservation	2/5	40
Hearing improvement	8/39	20.5
No hearing improvement	31/39	79.5
<b>Facial nerve preservation</b>		
Facial nerve preservation	18/28	64.3
No facial nerve preservation	10/28	35.7
Facial nerve improvement	3/14	21.4
No facial nerve improvement	11/14	78.6
Recurrence	2	7.2
Mean time interval after intervention to recurrence	9.5 ± 1.5 months	
Mortality	2	7.1

The mean follow-up duration for patients undergoing GKRS was  $11.3 \pm 2.3$  months. The GKRS procedures exhibited favorable tumor control, with 95.5% of cases achieving successful tumor control. Additionally, a mean relative volume reduction of  $34 \pm 6.7\%$  underscores the effectiveness of GKRS in reducing tumor size. The length of hospital stay for GKRS patients was relatively short, averaging  $4.9 \pm 2.1$  days. In the context of hearing preservation following GKRS, 90% of patients maintained their hearing, whereas hearing improvement was observed in 60.7% of cases. Facial nerve preservation following GKRS was successful in 94.7% of the patients, with a notable 50% improvement in facial nerve function.

In contrast, craniotomy procedures are associated with a mean follow-up duration of  $11.5 \pm 1.6$  months and a longer mean hospital stay of  $6.3 \pm 3.6$  days. Hearing preservation in craniotomy cases was achieved in 60% of patients, with hearing improvement observed in 20.5% of cases. Facial nerve preservation was successful in 64.3% of the craniotomy patients, and 21.4% experienced improvement in facial nerve function. The study also reported recurrence in 7.2% of cases after craniotomy, with a mean time interval of  $9.5 \pm 1.5$  months. Owing to VS's benign nature, the overall mortality rate for both GKRS and craniotomy is low, with 0% and 7.1% mortality, respectively.

## DISCUSSION

### Incidence and demographic trends

VS is one of the most prevalent benign primary brain tumors with an incidence rate of 2.2 per 100,000 person-years [2]. A study by Fernández-Méndez et al. found that the incidence rate of VS tends to increase each year due to improved access to diagnostic facilities and referral systems, leading to earlier diagnosis of smaller tumors. Similarly, Evans et al. reported an annual increase in VS patients, and Goldbrunner et al. attributed this to improved screening protocols for asymmetrical hearing loss, better access to advanced imaging, and improved resolution of MRI, resulting in an increased number of VS diagnoses and a smaller average tumor size at the time of diagnosis [2-4]. Consistent with previous studies, this study found that the number of VS patient admissions increased annually [3,4]. The majority of patients with VS in this study were female, consistent with a report by Boari et al. that VS is more common in younger individuals (<40 years of age) [5]. Similarly, Gupta et al. reported that VS patients typically present between the ages of 20-40, which is consistent with the findings of this study, in which 64% (n=56) of the patients were female and 33% (n=29) belonged to the same age group [6].

### Clinical presentations and symptomatology

The most common symptom observed in this study was hearing loss (71.5%), followed by disequilibrium (50%), headache (39.7%), and tinnitus (25%). This finding is consistent with other studies published before [2,4,7]. Hearing loss, tinnitus, and disequilibrium were the hallmark symptom of VS that often develops gradually, due to the slow growth of the tumor compressing and irritating the vestibulocochlear nerve [8].

Headache and visual impairment are indicators of elevated intracranial pressure (ICP) due to space-occupying lesions in the brain. Other symptoms related to increased ICP, including nausea, vomiting, confusion, and decreased level of consciousness, may also be present in patients with VS, particularly in large and giant VS. In some cases where compression occurs to the fourth ventricle, hydrocephalus may occur and require prompt CSF diversion procedures [2,9].

Compression of the facial nerve, leading to facial weakness or paralysis, reveals that the facial nerve travels in close proximity to the vestibulocochlear nerve. Growth of VS may also affect the trigeminal nerve, which manifests as numbness or a tingling sensation in the face. Less frequent symptoms, including cerebellar signs, may manifest because of the proximity of the tumor to the cerebellum. One of the main functions of cerebellum is to coordinate movement [8].

Based on the data analyzed, the authors determined that there is a trend towards admitting medium-to-large tumors to their institution. Specifically, in four cases, CSF diversion procedures were conducted prior to GKRS or craniotomy when symptoms of elevated ICP imaging findings supported this decision. In a separate study, Shin et al. reported that ventriculoperitoneal (VP) shunting was typically performed in patients with large ventricles and communicating hydrocephalus [10].

### Treatment modalities

In our institution, the availability of the GKRS provided treatment options and treatment combinations. This explains why the proportion of cases treated with radiosurgery or craniotomy tends to change every year. Patients with serviceable hearing and tumors with a diameter <30 mm would be recommended GKRS [11-13]. In special cases, however, giant tumors undergo GKRS, such as those aged >70 years or those not willing to undergo surgery. Age is a relative reason for patients not undergoing surgery, and good outcomes can still be achieved [14]. According to a study by Tosi et al. on the outcomes of Stereotactic Radiosurgery (SRS) for large VS, all treatment modalities demonstrated high tumor control rates and a

decline in pretreatment hearing. However, no significant facial nerve impairment was reported [15].

Despite the aforementioned reasons, the authors still recommend surgery as the first-line treatment for large and giant tumors for a better control rate [11]. With the availability of IOM, the trend of VS treatment has changed toward tumor resection, especially for medium to giant tumors. It is a crucial method for detecting facial nerve function intraoperatively while guiding the surgeon more safely for total resection [16,17]. This increase in craniotomies is mainly attributed to the advancements in IOM, which has enhanced the safety and efficacy of surgical resection. With better tools to monitor nerve function during surgery, surgeons are becoming more confident in achieving total or subtotal resection with minimal complications. The retrosigmoid approach was used in all patients who underwent surgery and presented with unserviceable hearing loss. The decision for choosing retrosigmoid approach reflects the prioritization of life-threatening conditions over functional preservation and surgeon's preference [18]. In the systematic review by Preet et al., retrosigmoid craniotomy with IOM has better long-term outcomes for large and giant tumors compared to radiosurgery [19]. Moreover, in their review, You et al. indicated that the retrosigmoid approach appears to be the most adaptable pathway for facial nerve preservation in the majority of tumor sizes in comparison to GKRS, although it is accompanied by a higher likelihood of postoperative pain and CSF fistula [20]. Concurrently, Lin et al. suggested that subtotal resection followed by observation or SRS, particularly for a large VS, can achieve long-term tumor control with improved CN preservation [21].

This trend towards craniotomy has significant clinical implications, including enhanced safety and efficacy, as well as improved long-term outcomes. Additionally, the availability of both craniotomy with IOM and GKRS provides neurosurgeons with a broader range of options. This enables a more personalized approach to patient care, taking into account factors such as tumor size, patient age, and overall health. This flexibility ensures that patients receive the most appropriate treatment for their specific condition, ultimately improving their overall prognosis and quality of life.

### Laterallization of tumor

In our study, the observed laterallization tendency was to the left side (53.4%). Bilateral presentation of VS was found in 4.5% of the patients. Bilateral VS is a hallmark presentation of neurofibromatosis type 2 (NF2). NF2 needs to be diagnosed using genetic testing, however it is still not available in our institution during this study period [22].

### Types of referring physicians

Our institution is one of the largest referral centers in Indonesia, which maybe the reason more than half of the treated cases were referred from outside the RSCM. Currently, not all centers in Indonesia have GKRS facilities within the hospital. For this reason, the number of cases treated with GKRS was also higher than that of those who underwent surgical treatment especially for small size tumors.

This study also showed the central role of neurosurgeons in the referral system, which highlights the specialized expertise required for VS management. A direct referral process from the general practitioner may expedite the patient's process of intervention, thereby improving the prognosis.

### Surgical decisions

The decision-making process for managing vestibular schwannomas involves a comprehensive evaluation of tumor characteristics and clinical considerations. GKRS is preferred for smaller tumors (<3 cm), constituting 76.7% of cases, with a median volume of 8 cm<sup>3</sup> and a precise dose of 15 [20]. Preservation of hearing and facial nerves guide 15% of the GKRS decisions. Surgeon's preference influenced 8.3% of cases, highlighting the individualized nature of clinical judgment. This finding is also supported by a previous study which stated that GKRS is superior for smaller VS [23].

In contrast, craniotomy was reserved for larger tumors (>3 cm), which comprised 96.4% of the cases. The extent of surgical resection varied, with 28.6% of patients achieving gross total resection, emphasizing the surgical goal of complete resection. The decision-making landscape is shaped by a careful balance between tumor size, preservation objectives, and individual clinical judgment, reflecting the tailored approach in vestibular schwannoma management [14]. According to Kleijwegt et al., tumor location, a short duration of hearing loss, and balance disorders are considered to be the most effective predictors for adjusting an initial conservative treatment approach [24].

### Clinical course

The overall symptoms of patients' post-intervention declined over the course of immediately after intervention and at 3, 6, and 12-month follow-up after intervention, indicating the effectiveness of both the GKRS and craniotomy. Despite the overall positive clinical course, there were 2 deaths in the craniotomy group. Patient death was due to coronavirus disease 2019 (COVID-19) infection during the pandemic and was not related to surgical complications. In contrast, no deaths were observed in the GKRS group.

## Post-operative outcomes

Table 5 presents the pre-operative and post-operative outcomes immediately, and at 3-month, 6-month, and 12-month intervals after the operation. The number of patients experiencing hearing loss fluctuates over these periods, with counts of 63, 65, 61, 52, and 42 respectively. These fluctuations suggest that patients undergoing both craniotomy and GKRS may experience temporary impacts on auditory structures or nerves. This can be attributed to manipulation of nearby structures during surgery and temporary swelling or pressure changes that affect hearing. Over time, as the body heals and the temporary effects of surgery subside, hearing loss can improve. Therefore, consistent follow-up for monitoring and rehabilitation after VS management is crucial to support hearing recovery and optimize outcomes.

GKRS demonstrated efficacy with a high degree of tumor control (95.5%) and favorable hearing (90%) and facial nerve (94.7%) preservation outcomes. This study is consistent with previous studies reported [13,25]. Berkovitz et al. reported 104 (29.7%) participants who reported that they currently maintain useful hearing in the GKRS-treated tumor ear [13]. Similarly, in their study Smith et al. found that most patients who underwent GKRS for mildly to moderately symptomatic vestibular schwannomas experienced effective symptomatic relief from prior tinnitus (83.7%), vertigo, dizziness and disequilibrium (62.7%), functional neurological disorder (90.0%), transient neurological deficits (79.2%), and lateralize headache (94.7%) following GKRS, but not existing hearing loss (1.0%) [25]. The shorter hospital stay and lower recurrence rates further highlight the benefits of GKRS. Craniotomy, which is associated with longer hospital stay and lower rates of hearing and facial nerve preservation, remains a crucial intervention for larger tumors and cases with severe neurological deficits.

## Strengths, limitations and future directions

The strength of this study lies in its provision of comprehensive data on the symptomatology, diagnosis, treatment, and management of VS at one of the national referral centers in Indonesia. This is the first study of its kind in the country, serving as a crucial foundation for future research and the development of national policies regarding VS management. Additionally, the extensive dataset from our center allows for a thorough analysis of VS management practices across Indonesia. We hope that our findings will contribute to improving VS management nationwide and help bridge the gap between rural and urban health-care services.

Conversely, our study is limited because we could not compare the incidence rates of vestibular schwannomas in Indonesia's population or other centers.

To capture a more accurate picture of the incidence of VS in Indonesia, a national registry should be established. Such a registry would enable us to investigate the relationship between tumor size and presenting symptoms, and also consider the possibility that cases may be more prevalent than those that have been referred to our center because of the limitations of the current referral system. A national registry could also serve as a foundation for evidence-based guidelines, targeted interventions, and the facilitation of multidisciplinary collaborations between medical specialists in Indonesia. Multidisciplinary collaborations between neurosurgeons, neurologists, otolaryngologists, and radiation oncologists ensure better comprehensive care for individuals affected by VS [26].

In considering future directions, the establishment of a national registry has emerged as a crucial step in facilitating evidence-based medicine tailored to Indonesian demographics. Collaborative efforts involving multiple institutions would provide a more comprehensive dataset, enabling a better understanding of vestibular schwannoma epidemiology, clinical course, and outcomes in Indonesia. Additionally, fostering international collaboration would facilitate the exchange of knowledge and expertise, contributing to advancements in both research and clinical practice.

The transition from GKRS to craniotomy, influenced by the implementation of IOM, exemplifies the developing nature of the neurosurgical techniques. Future research should explore the implications of advancements in neurosurgical technology that may lead to improved patient outcomes.

## CONCLUSION

This study examines the demographic trends, clinical presentations, treatment modalities, and outcomes of vestibular schwannoma at one of the largest national referral centers in Indonesia, which also serves as a reflection of the general Indonesian population. The number of VS cases in our center has increased annually, which indicates better detection and diagnosis of VS. Notably, hearing loss, disequilibrium, and headache are the most common symptoms of VS, along with various other clinical manifestations. The treatment options for VS vary, and the selection of treatment options is based on the presenting symptoms and tumor size. GKRS demonstrated efficacy in tumor control, hearing, and facial nerve preservation, with shorter hospital stays, whereas craniotomy is preferable for larger tumors and cases with severe deficits. In recent years, there has been a transition from GKRS to craniotomy, which is influenced by the implementation of IOM.



The study highlights several key findings and provides specific recommendations for clinical practice. Firstly, the annual rise in VS cases underscores the importance of early detection and diagnostic improvements. The identification of hearing loss, disequilibrium, and headache as the primary symptoms suggests that these should be prioritized in clinical assessments. In terms of treatment efficacy, GKRS shows superior outcomes for smaller tumors, while craniotomy is essential for larger tumors, emphasizing the need for individualized treatment plans. Additionally, the adoption of IOM in surgical procedures enhances safety and efficacy, suggesting its broader application could benefit surgical outcomes.

The study recommends enhancing screening protocols and access to advanced imaging techniques to

facilitate early diagnosis and treatment. It also highlights the importance of individualized treatment plans based on tumor size and presenting symptoms, with a focus on maximizing tumor control and preserving nerve function. Furthermore, the wider implementation of IOM in surgical procedures could improve the safety and efficacy of craniotomies for VS. Finally, this study also highlights the urgent need for a national registry in Indonesia to better understand the epidemiology of VS. This registry can serve as a foundation for evidence-based guidelines tailored to Indonesian demographic characteristics. Multidisciplinary collaboration and international partnerships are essential for improving patient prognosis.

*Conflicts of interest:* none declared

*Financial support:* none declared

## REFERENCES

- Winn HR, Youmans JR. Youmans & Winn neurological surgery. 8th ed. Philadelphia: Elsevier; 2023 Aug.
- Fernández-Méndez R, Wan Y, Axon P, Joannides A. Incidence and presentation of vestibular schwannoma: a 3-year cohort registry study. *Acta Neurochir (Wien)* [Internet]. 2023 Jul 15 [cited 2023 Sep 5];165(10):2903-11. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542718/>.
- Evans DGR, Moran A, King A, Saeed S, Gurusinge N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought. *Otol Neurotol*. 2005 Jan;26(1):93-7. doi: 10.1097/00129492-200501000-00016.
- Goldbrunner R, Weller M, Regis J, Lund-Johansen M, Stavrinou P, Reuss D, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. *Neuro Oncol*. 2020;22(1):31-45. doi: 10.1093/neuonc/noz153.
- Boari N, Bailo M, Gagliardi F, Franzin A, Gemma M, del Vecchio A, et al. Gamma Knife radiosurgery for vestibular schwannoma: clinical results at long-term follow-up in a series of 379 patients: Clinical article. *J Neurosurg*. 2014 Dec;121(Suppl\_2):123-42. doi: 10.3171/2014.8.GKS141506.
- Gupta VK, Thakker A, Gupta KK. Vestibular schwannoma: what we know and where we are heading. *Head Neck Pathol*. 2020;14:1058-66. doi: 10.1007/s12105-020-01155-x.
- Soltys SG, Milano MT, Xue J, Tomé WA, Yorke E, Sheehan J, et al. Stereotactic radiosurgery for vestibular schwannomas: tumor control probability analyses and recommended reporting standards. *Int J Radiat Oncol Biol Phys*. 2021 May;110(1):100-11. doi: 10.1016/j.ijrobp.2020.11.019.
- Talesanab MH, Hougaard DD. Transient profound hearing loss and severe facial nerve palsy in schwannomas within the internal acoustic canal: a case report. *Oncol Lett*. 2023 Jan;25:126. doi: 10.3892/ol.2023.13712.
- Lin AL, Avila EK. Neurologic emergencies in the cancer patient: diagnosis and management. *J Intensive Care Med*. 2017 Feb;32(2):99-115. doi: 10.1177/0885066615619582.
- Shin DW, Song SW, Chong S, Kim YH, Cho YH, Hong SH, Kim JH. Treatment outcome of hydrocephalus associated with vestibular schwannoma. *J Clin Neurol*. 2021;17(3):455-62. doi: 10.3988/jcn.2021.17.3.455.
- Yeole U, Prabhuraj AR, Arivazhagan A, Narasingarao KVL, Vazhayil V, Bhat D, et al. Gamma knife radiosurgery for large vestibular schwannoma more than 10 cm3: A single-center Indian study. *J Neurol Surg B Skull Base*. 2022 Jun;83(S 02):e343-52. doi: 10.1055/s-0041-1729977.
- Myrseth E, Møller P, Pedersen PH, Lund-Johansen M. Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. *Neurosurgery*. 2009 Apr;64(4):654-63. doi: 10.1227/01.NEU.000034-684.60443.55.
- Berkowitz O, Han YY, Talbott EO, Iyer AK, Kano H, Kondziolka D, et al. Gamma knife radiosurgery for vestibular schwannomas and quality of life evaluation. *Stereotact Funct Neurosurg*. 2017;95(3):166-73. doi: 10.1159/0004721566.
- Strickland BA, Rennert R, Zada G, Shahrestani S, Russin JJ, Friedman RA, et al. Surgical outcomes following vestibular schwannoma resection in patients over the age of sixty-five. *J Neurol Surg B Skull Base*. 2023 Apr;84(02):129-35. doi: 10.1055/a-1771-0504.
- Tosi U, Lavieri MET, An A, Maayan O, Guadix SW, DeRosa AP, et al. Outcomes of stereotactic radiosurgery for large vestibular schwannomas: a systematic review and meta-analysis. *Neuro Oncol Pract*. 2021;8(4):405-16. doi: 10.1093/nop/npab011.
- Arlt F, Kasper J, Winkler D, Jähne K, Fehrenbach MK, Meixensberger J, et al. Facial nerve function after microsurgical resection in vestibular schwannoma under neurophysiological monitoring. *Front Neurol*. 2022 May 24;13:850326. doi: 10.3389/fneur.2022.850326.
- Youssef AS, Downes AE. Intraoperative neurophysiological monitoring in vestibular schwannoma surgery: advances and clinical implications. *Neurosurg Focus*. 2009 Oct;27(4):E9. doi: 10.3171/2009.8.FOCUS09144.
- Dejam D, Ding K, Duon C, Ong V, Yang I. Hearing preservation in a vestibular schwannoma patient via a retrosigmoid approach. *Cureus*. 2021 Sep;13(9):e18403. doi: 10.7759/cureus.18403.
- Preet K, Ong V, Sheppard JP, Udawatta M, Duong C, Romiyo P, et al. Postoperative hearing preservation in patients undergoing retrosigmoid craniotomy for resection of vestibular schwannomas: A systematic review of 2034 patients. *Neurosurg*. 2020;86(3):332-42. doi: 10.1093/neuros/nyz147.
- You YP, Zhang JX, Lu AL, Liu N. Vestibular schwannoma surgical treatment. *CNS Neurosci Ther*. 2013;19:289-93. doi: 10.1111/cns.12080.
- Lin EP, Crane BT. The management and imaging of vestibular schwannomas. *Am J Neuroradiol*. 2017 Nov;38:2043-43. doi: 10.3174/ajnr.A5213.
- Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma. *Neuro-Oncol Adv*. 2020 Nov;3(1):1-13. doi: 10.1093/noonj/vdaa153.
- Aman RA, Petonengan DAA, Hafif M, Santoso F. Hearing preservation, facial nerve dysfunction, and tumor control in small vestibular schwannoma: a systematic review of gamma knife radiosurgery versus microsurgery. *J Clin Neurol*. 2023 May;19(3):304-11. doi: 10.3988/jcn.2022.0116.
- Kleijwegt M, Bettink F, Malessy M, Putter H, van der Mey A. Clinical predictors leading to change of initial conservative treatment of 836 vestibular schwannomas. *J Neurol Surg B*. 2020;81:15-21. doi: 10.1055/s-0039-1678708.
- Smith DR, Saadatmand HJ, Wu CC, Black PJ, Wu YR, Lesser J, et al. Treatment outcomes and dose rate effects following gamma knife stereotactic radiosurgery for vestibular schwannomas. *Neurosurgery*. 2019 Dec;85(6). doi: 10.1093/neuros/nyz229.
- Greene J, Al-Dhamir MA. Acoustic neuroma [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan [updated 2023 Aug 17; cited 2023 Oct 23]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470177/>.